

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



EuroEyes International Eye Clinic Limited

德視佳國際眼科有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1846)

PROFIT ALERT

This announcement is made by EuroEyes International Eye Clinic Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board (the “**Board**”) of directors (the “**Directors**” and each a “**Director**”) of the Company would like to inform the shareholders of the Company (the “**Shareholders**”) and potential investors that, based on a preliminary assessment of the unaudited consolidated management accounts of the Group for the year ended 31 December 2022 (the “**Year**”) and the information currently available to the Board, the Group expects to record a profit attributable to owners of the Company in the range of approximately HK\$85 million to approximately HK\$90 million, as compared to approximately HK\$133.6 million for the year ended 31 December 2021 (“**Last Year**”).

The Board considers that such expected decrease in the profit attributable to owners of the Company for the Year as compared to Last Year was principally attributable to the combined effects of (i) the expected net foreign exchange losses due to the fluctuations of foreign exchange rate; (ii) the negative impact of the Russia-Ukraine crisis on the consumption sentiment of the younger generation in Europe by reducing the number of refractive laser procedures, a type of eye surgery for young patients, compared to the steady demand for trifocal lens exchange, a type of eye surgery for middle-aged and elderly patients; and (iii) the decrease in the number of eye surgeries in the People’s Republic of China (the “**PRC**”) considering the compulsory closure of the clinics and business disruption caused by Omicron variant outbreaks in the first half of 2022. Also, the outbreak of COVID-19 cases in the fourth quarter of the Year temporarily affected normal social activities. However, in view of the zero-Covid control measures being dismantled in December 2022 by the PRC government, all of the Group’s clinics in the PRC have resumed normal operation, and the demand for eye surgeries has seemed to be increased.

The information contained in this announcement is only based on the preliminary assessment of information currently available and the unaudited consolidated management accounts of the Group for the Year by the management of the Company, and is not based on any figures or information audited or reviewed by the Company’s independent auditor and/or audit committee and may be also subject to further adjustment. The Company is still in the process of finalising the final results of the Group for the year ended 31 December 2022.

Further details of the Group's financial results and performance will be disclosed in the Company's results announcement for the year ended 31 December 2022 in compliance with the requirements of the Listing Rules, which shall prevail over the information contained herein. The Board wishes to emphasise that the results of the Group for the year ended 31 December 2022 may be affected by some other factors. As such, the above information is provided for Shareholders' and potential investors' reference only.

Shareholders and potential investors are advised to read carefully the announcement of the annual results of the Group for the year ended 31 December 2022, which is expected to be published by the end of March 2023.

Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
EuroEyes International Eye Clinic Limited
Dr. Jørn Slot Jørgensen
Chairman and Executive Director

Hong Kong, 17 March 2023

As at the date of this announcement, the Board comprises Dr. Jørn Slot Jørgensen, Dr. Markus Braun, Mr. Jannik Jonas Slot Jørgensen and Professor Dan Zoltan Reinstein as executive Directors; Mr. Marcus Huascar Bracklo as non-executive Director; and Mr. Hans Helmuth Hennig, Ms. Katherine Rong Xin and Mr. Philip Duncan Wright as independent non-executive Directors.